AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04568473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRG Barrier Coat (By SHOFU Inc., Japan)
Description: PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
Study NCT02887638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Profile Analysis (Physical therapy Intervention)
Description: The Individual Profile Analysis consists of the following components:~* Analysis of the sitting-posture profile:~  o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~* Analysis of the dural profile before and after the provoking task:~  o Determination of the dural sensitivity by the use of the slump-test~* Analysis of the pain profile before and after the provoking task:~  * Determination of pressure pain sensitivity by the use of pressure algometry~ * Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire
Study NCT04458545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxy(Gly)4-sKLH vaccine - High Dose
Description: Oxy(Gly)4-sKLH vaccine - high dose
Study NCT04458545 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oxy(Gly)4-sKLH vaccine
Description: Oxy(Gly)4-sKLH vaccine - Placebo
Study NCT04735809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Cell Algae Fermentate
Description: Contains at minimum 50% Beta Glucan
Study NCT04735809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose
Study NCT01153672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT01153672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01153672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT01916720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848 40 mg
Description: Study Drug
Study NCT02764138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building a Strong Identity and Coping Skills
Description: Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
Study NCT03744936 — intervention group
Intervention type: OTHER
Intervention: Feedback
Description: Study team members will conduct interviews with subjects to gather feedback on Atrial Fibrillation experiences
Study NCT06790303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: Feladilimab will be administered.
Study NCT06790303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered
Study NCT03055013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Undergo nephrectomy
Study NCT03055013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nephrectomy
Description: Undergo nephrectomy
Study NCT03055013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03055013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study NCT01916720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848 80 mg
Description: Study Drug
Study NCT03055013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03055013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03055013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03055013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02107703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally
Study NCT02107703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM
Study NCT02107703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Administered IM
Study NCT02107703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study NCT02484404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID) Ph II - MEDI4736 + Olaparib at RP2D
Study NCT02484404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily) Ph II - MEDI4736 + Cediranib at RP2D
Study NCT02484404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Ph I - Durvalumab will be administered once every 2 weeks for 12 months.
Study NCT04868227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FULTIUM D3 VITAMIN D3
Description: VITAMIN D3 SUPPLEMENT
Study NCT00001160 — intervention group
Intervention type: DRUG
Intervention: 68-Gallium Dotatate
Description: For evaluation risk/benefit evaluation
Study NCT01153672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-18 16 alpha-fluoroestradiol
Description: Correlative studies
Study NCT01153672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study NCT01916720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study Drug
Study NCT01916720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study Drug
Study NCT04048928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maximal strength training
Description: The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
Study NCT01704378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
Study NCT01466647 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AXL1717
Description: A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
Study NCT03839979 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BIOLINE HCV kits
Description: We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.
Study NCT03839979 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ACCU-CHEK kits
Description: For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.
Study NCT01153672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO
Study NCT01153672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO
Study NCT01153672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO
Study NCT01153672 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT02163772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracordal hyaluronate injection
Study NCT02795455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure (IE)
Description: Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
Study NCT02795455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Therapy-Weight Gain Control (FBT-WG)
Description: Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
Study NCT02795455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: meal replacement shake
Study NCT03828500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistant-encouraged fasting up to ASA/CAS guideline limits
Description: Research Assistant encourages patient to drink clear fluids up to 2 hour limit before surgery, in accordance with the latest ASA and CAS guidelines.
Study NCT00905372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2062430
Description: 400 mg intravenously (IV) every 4 weeks for 80 weeks
Study NCT00905372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously (IV) every 4 weeks for 80 weeks
Study NCT04163913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change in User interfaces of Cirvo compression device application.
Description: Comparison of 2 versions of the Circo user interface
Study NCT04163913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in User interfaces of Cirvo compression device application.
Description: Comparison of 2 versions of the Circo user interface
Study NCT04163913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change in Satisfaction in use of Cirvo device
Description: Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
Study NCT03839979 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ErKameter 3000 mercury manometer
Description: For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.
Study NCT02216734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother support groups for HIV+ mothers
Description: Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
Study NCT03806790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 foam
Description: Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
Study NCT03806790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovobet® ointment
Description: Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
Study NCT03280498 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intubation
Description: elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
Study NCT04163913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in Satisfaction in use of Cirvo device
Description: Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
Study NCT02074904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Study NCT04829643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited
Study NCT02074904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02299804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levophencynonate Hydrochloric
Description: this drug is M receptor inhibitor
Study NCT02299804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredient
Study NCT04812860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042
Description: Tablet, Dosing frequency: once daily, Route of administration: oral
Study NCT04812860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042
Description: Tablet,Dosing frequency: once daily, Route of administration: oral
Study NCT04812860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride ER
Description: Tablet,Dosing frequency: once daily, Route of administration: oral
Study NCT04812860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet,Dosing frequency: once daily, Route of administration: oral
Study NCT01105949 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed nasal strip
Description: Marketed nasal strip
Study NCT01105949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexGen AB 2R11
Description: Nasal strip prototype
Study NCT01105949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexGen JB Organic PET/PE
Description: Nasal strip
Study NCT00823160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sternotomy
Description: Sternotomy performed after finding blood in the pericardial sac
Study NCT00823160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subxyphoid window
Description: Subxyphoid window performed after the finding of blood in the pericardial sac
Study NCT05106439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study competition-related mobile notification
Description: Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
Study NCT05106439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app
Description: The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
Study NCT05106439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app competition scoreboard and history
Description: Participant can view their current competition scoreboard and competition history at any time via the study app.
Study NCT00837642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Full transthoracic echocardiography will be performed.
Study NCT04501172 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire completion
Description: Participants are contacted through social networks (Facebook) which provide a link to website that contains the questionnaire. Then, they complete the questionnaire which consists of the following 2 parts:~1. participant's demographic characteristics with questions regarding age, visual acuity - refractive error, spectacles and contact lenses use, and compliance to mask-wearing directives.~2. 20 items that construct 5 subscales: a) near vision (5 items), b) distance vision (3 items), c) ocular discomfort (3 items), d) driving (2 items), e) limitations (3 items), need for help (2 items), work collaboration (1 item), and emotional impact (1 item).~The impact of spectacles on the compliance of Greek people to mask-wearing directives will be assessed via this questionnaire.
Study NCT00466661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: 666 mg po TID
Study NCT04568473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRG Barrier Coat (By SHOFU Inc., Japan)
Description: PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
Study NCT04568473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMBRACE™ Varnish by (Pulpdent Corporation, USA)
Description: 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
Study NCT04568473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMBRACE™ Varnish by (Pulpdent Corporation, USA)
Description: 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
Study NCT02451332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated seasonal flu vaccine
Description: Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
Study NCT00466661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tabs po TID
Study NCT02069704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab biosimilar (BEVZ92)
Description: Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.
Study NCT02069704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin® (bevacizumab, reference product)
Description: Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.
Study NCT03476434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chromoendoscopy with indigo carmine
Description: the lumen of the colon is sprayed in a segmental fashion using 0.4% indigo carmine delivered via a specially designed dye spray catheter (Olympus PW-5V1) or via the accessory channel with a 50cc syringe filled with indigo carmine and air.
Study NCT03949621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study NCT03949621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study NCT02448017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Herbst appliance
Description: Orthodontic functional appliance
Study NCT02448017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin block appliance
Description: Orthodontic functional appliance
Study NCT03622541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 200mg
Description: Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.